Risk of postacute sequelae of COVID-19 and oral antivirals in adults aged over 60 years: A nationwide retrospective cohort study

Risk of postacute sequelae of COVID-19 and oral antivirals in adults aged over 60 years: A nationwide retrospective cohort study

Objectives: To investigate the association between oral antiviral administration and postacute sequelae of COVID-19 (PASC) risk in Korea. Methods: This retrospective cohort study used data from the Korea Disease Control and Prevention Agency and the Health Insurance Review and Assessment Service. We...

Full description

Saved in:
Bibliographic Details
Main Authors: Hyejin Joo, Eunji Kim, Kyungmin Huh, Gi Hwan Bae, Hyungmin Lee, Jungyeon Kim, Dong-Hwi Kim, Min-Gyu Yoo, Il Uk Jo, Poong Hoon Lee, Geun Woo Lee, Hee Sun Jung, Jaehun Jung
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:International Journal of Infectious Diseases
Subjects:
COVID-19
Antiviral agents
Postacute sequelae of COVID-19 (PASC)
Nirmatrelvir/ritonavir
Molnupiravir
Retrospective cohort study
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971225000736
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives: To investigate the association between oral antiviral administration and postacute sequelae of COVID-19 (PASC) risk in Korea. Methods: This retrospective cohort study used data from the Korea Disease Control and Prevention Agency and the Health Insurance Review and Assessment Service. We analyzed data from COVID-19 patients aged >60 years from January to December 2022. The primary outcome was the occurrence of 27 PASCs within 30-120 days after COVID-19 diagnosis. The hazard ratio was calculated using the Cox proportional hazards model. Results: Nirmatrelvir/ritonavir significantly reduced the risk of cardiovascular diseases, including heart failure and cardiomyopathies (adjusted hazard ratio [aHR], 0.86), cardiac dysrhythmias (aHR, 0.83), and ischemic stroke (aHR, 0.88). Moreover, it also lowered the risk of hospitalization due to respiratory diseases including chronic obstructive pulmonary disease (aHR, 0.92), and decreased renal disorders including dialysis needs (aHR, 0.57), and acute renal failure (aHR, 0.85). Molnupiravir reduced the risk of ischemic stroke (aHR, 0.84) and other cerebrovascular diseases (aHR, 0.84). Respiratory conditions decreased by approximately 13-14% (aHR, 0.87 and 0.86, respectively). Conclusions: Nirmatrelvir/ritonavir and molnupiravir administration in ambulatory patients were associated with decreased PASC risk; thus, oral antivirals may mitigate the indirect Severe acute respiratory syndrome coronavirus 2 infection effects.
ISSN:1201-9712

Similar Items